Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03470922 · ClinicalTrials.gov registry record · Phase 2
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 2
- Development phase
- 714
- Enrollment target
- 20
- Study locations
NCT03470922 is a Phase 2 study of Melanoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 714 participants, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT03470922, a Phase 2 study of Melanoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 714 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Relatlimab
Study Locations (20)
California
- Local Institution - 0020 - Los Angeles
- Coastal Integrative Cancer Care - San Luis Obispo
- Local Institution - 0116 - Santa Barbara
Florida
- Local Institution - 0013 - Jacksonville
- Local Institution - 0117 - Orlando
- Local Institution - 0007 - Tampa
Maryland
- Local Institution - 0077 - Baltimore
- Local Institution - 0120 - Baltimore
Massachusetts
- Local Institution - 0014 - Boston
- Local Institution - 0134 - Boston
Minnesota
- Local Institution - 0009 - Minneapolis
- Local Institution - 0011 - Rochester
Arizona
- Local Institution - 0010 - Tucson
District of Columbia
- Local Institution - 0012 - Washington D.C.
Georgia
- Local Institution - 0038 - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2018-04-11 |
| Est. Completion | 2030-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03470922
The ClinicalTrials.gov registry entry for NCT03470922 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03470922 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT03470922 about?
NCT03470922 is a clinical study titled "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma". The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
What is the current status of trial NCT03470922?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 714 participants. The study started on 2018-04-11. Estimated completion is 2030-12-15.
What conditions does trial NCT03470922 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT03470922?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Relatlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03470922?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03470922 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.